ADMA Biologics, Inc. Fundamental Analysis (NASDAQ: ADMA)
ADMA Biologics, Inc. (NASDAQ: ADMA) shows strong financial fundamentals with a PE ratio of 13.19, profit margin of 32.98%, and ROE of 39.59%. The company generates $0.5B in annual revenue with strong year-over-year growth of 19.63%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 80.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze ADMA's fundamental strength across five key dimensions:
Efficiency Score
ExcellentADMA demonstrates superior asset utilization.
Valuation Score
ExcellentADMA trades at attractive valuation levels.
Growth Score
ModerateADMA shows steady but slowing expansion.
Financial Health Score
ExcellentADMA maintains a strong and stable balance sheet.
Profitability Score
ExcellentADMA achieves industry-leading margins.
Key Financial Metrics
Is ADMA Expensive or Cheap?
P/E Ratio
ADMA trades at 13.19 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ADMA's PEG of -0.76 indicates potential undervaluation.
Price to Book
The market values ADMA Biologics, Inc. at 5.31 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 9.08 times EBITDA. This is generally considered low.
How Well Does ADMA Make Money?
Net Profit Margin
For every $100 in sales, ADMA Biologics, Inc. keeps $32.98 as profit after all expenses.
Operating Margin
Core operations generate 42.26 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $39.59 in profit for every $100 of shareholder equity.
ROA
ADMA Biologics, Inc. generates $24.69 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
ADMA Biologics, Inc. generates strong operating cash flow of $138.84M, reflecting robust business health.
Free Cash Flow
ADMA Biologics, Inc. generates strong free cash flow of $118.28M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.51 in free cash annually.
FCF Yield
ADMA converts 5.29% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
13.19
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.76
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.31
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.30
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.50
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.97
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.40
vs 25 benchmark
ROA
Return on assets percentage
0.25
vs 25 benchmark
ROCE
Return on capital employed
0.36
vs 25 benchmark
How ADMA Stacks Against Its Sector Peers
| Metric | ADMA Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 13.19 | 30.58 | Better (Cheaper) |
| ROE | 39.59% | 579.00% | Weak |
| Net Margin | 32.98% | 24148.00% | Weak |
| Debt/Equity | 0.50 | 0.52 | Neutral |
| Current Ratio | 6.97 | 5.66 | Strong Liquidity |
| ROA | 24.69% | -58.00% (disorted) | Strong |
ADMA outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews ADMA Biologics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
336.83%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
170.12%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
117.86%
Industry Style: Defensive, Growth, Innovation
High Growth